IRONWOOD is a Bio that commits the crime of making money. $94 million!>They are a one product story and that has held it back. If they could get another shot on goal this would become such an attractive TAKEOUT CANDIDATE. PartnerAbbVie ABBV, Ironwood’s sole marketed product — Linzess (linaclotide) — generated net sales of almost $232.3 million in the United States, up 8% year over year. Ironwood and AbbVie equally share Linzess’ brand collaboration profits or losses. The sales growth was driven by strong demand for Linzess, partially offset by the lower net price of the drug and inventory channel fluctuations. Ironwood's share of net profits from the sales of Linzess in the United States (included in collaborative revenues) was $94.3 million in the first quarter, up 9.7% year over year. Per data provided by IQVIA, the prescription volume for Linzess capsules in the first quarter increased about 11% year over year. The company recorded $3.2 million in royalties and other revenues compared with $2.9 million in the year-ago period. We note that Ironwood has agreements with two partners — Astellas Pharma and AstraZenecaAZN — related to the development and commercialization of Linzess in Japan and China, respectively. Ironwood records royalties on sales of Linzess from Astellas and AstraZeneca in their respective territories. Wouldn't ABBV like to swallow up IRWD ? I would think so.> Ironwood Pharmaceuticals, Inc.IRWD reported first-quarter 2022 adjusted earnings of 21 cents per share, missing the Zacks Consensus Estimate of 27 cents. The company had reported adjusted earnings of 24 cents per share in the year-ago quarter. Total revenues of $97.5 million beat the Zacks Consensus Estimate of $95.49 million. Revenues were up almost 9.8% year over year. Shares of Ironwood were down 1.3% on May 5, following lower-than-expected earnings. However, the company’s shares have gained 5.1% so far this year against the industry’s decrease of 19.7%. RS story probably because it's an attractive M&A candidate.... I think you can add IRWD to your portfolios...
I don't know if THE SAVANT speaking here-- why did I just post on IRWD.... I do like the idea a lot. Here's some coverage from April. Of note is the exclusivity to 2029<--- Ironwood initiated with an Overweight at Piper Sandler 04/22 IRWD Piper Sandler analyst David Amsellem initiated coverage of Ironwood Pharmaceuticals with an Overweight rating and $16 price target. The company's primary value-driver, Linzess, benefits from market leadership, stable commercial dynamics, and certainty regarding its exclusivity runway into March 2029, Amsellem tells investors in a research note. He believes the stock offers an attractive risk/reward profile given a current enterprise value of $1.8B.
EXECUTE GUMMY NO 1!!! GO TIME!--> (SQZ) FLAT AT OPEN. 3.3500-0.0300(-0.89%) As of May 24 04:00PM EDT. Market open.
execute gummy No 2!!!! GO TIME--> Express, Inc. (EXPR) 2.4345+0.0545(+2.2899%) As of 09:33AM EDT. Market open.
Pray For Us Folks! // I have a bunch of stuff to do I won't be able to manage anything -- Back at 3:00 BE CAREFUL OUT HERE! ~SI